Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Alpine Immune Sciences

Nasdaq:ALPN
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALPN
Nasdaq
$48M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. The last earnings update was 135 days ago. More info.


Add to Portfolio Compare Print
  • Alpine Immune Sciences has significant price volatility in the past 3 months.
ALPN Share Price and Events
7 Day Returns
4.6%
NasdaqGM:ALPN
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-63.8%
NasdaqGM:ALPN
1.6%
US Biotechs
-9.1%
US Market
ALPN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alpine Immune Sciences (ALPN) 4.6% -22.3% -35.9% -63.8% - -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • ALPN underperformed the Biotechs industry which returned 1.6% over the past year.
  • ALPN underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
ALPN
Industry
5yr Volatility vs Market
Related Companies

ALPN Value

 Is Alpine Immune Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alpine Immune Sciences. This is due to cash flow or dividend data being unavailable. The share price is $2.48.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alpine Immune Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alpine Immune Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ALPN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-2.73
NasdaqGM:ALPN Share Price ** NasdaqGM (2020-03-27) in USD $2.48
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alpine Immune Sciences.

NasdaqGM:ALPN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ALPN Share Price ÷ EPS (both in USD)

= 2.48 ÷ -2.73

-0.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alpine Immune Sciences is loss making, we can't compare its value to the US Biotechs industry average.
  • Alpine Immune Sciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Alpine Immune Sciences's expected growth come at a high price?
Raw Data
NasdaqGM:ALPN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
4.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alpine Immune Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alpine Immune Sciences's assets?
Raw Data
NasdaqGM:ALPN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $1.87
NasdaqGM:ALPN Share Price * NasdaqGM (2020-03-27) in USD $2.48
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:ALPN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ALPN Share Price ÷ Book Value per Share (both in USD)

= 2.48 ÷ 1.87

1.32x

* Primary Listing of Alpine Immune Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alpine Immune Sciences is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Alpine Immune Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alpine Immune Sciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALPN Future Performance

 How is Alpine Immune Sciences expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alpine Immune Sciences expected to grow at an attractive rate?
  • Unable to compare Alpine Immune Sciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Alpine Immune Sciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Alpine Immune Sciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ALPN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ALPN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 4.6%
NasdaqGM:ALPN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 78.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ALPN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ALPN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 116 -7 2
2023-12-31 11 -70 2
2022-12-31 0 -71 2
2021-12-31 0 -63 3
2020-12-31 1 -54 4
2020-03-28
2019-12-31 1 -48 4
NasdaqGM:ALPN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 1 -39 -47
2019-06-30 1 -36 -48
2019-03-31 0 -35 -44
2018-12-31 1 -28 -36
2018-09-30 1 -25 -30
2018-06-30 1 -22 -15
2018-03-31 1 -19 -11
2017-12-31 2 -17 -8
2017-09-30 2 -13 -5
2017-06-30 3 -9 -7
2017-03-31 3 -6 -3
2016-12-31 3 -4 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alpine Immune Sciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Alpine Immune Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ALPN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Alpine Immune Sciences Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ALPN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.19 -0.11 -0.26 2.00
2023-12-31 -1.85 -1.71 -1.99 2.00
2022-12-31 -2.04 -1.89 -2.18 2.00
2021-12-31 -2.55 -1.89 -3.40 3.00
2020-12-31 -2.34 -1.42 -2.97 4.00
2020-03-28
2019-12-31 -2.54 -2.32 -2.63 4.00
NasdaqGM:ALPN Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -2.73
2019-06-30 -2.97
2019-03-31 -2.94
2018-12-31 -2.63
2018-09-30 -2.14
2018-06-30 -1.18
2018-03-31 -1.13
2017-12-31 -1.20
2017-09-30 -1.43
2017-06-30 -10.89
2017-03-31 -7.08
2016-12-31 -2.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alpine Immune Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Alpine Immune Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alpine Immune Sciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALPN Past Performance

  How has Alpine Immune Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alpine Immune Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alpine Immune Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Alpine Immune Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alpine Immune Sciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alpine Immune Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alpine Immune Sciences Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ALPN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.86 -46.85 9.88
2019-06-30 0.57 -47.51 9.27
2019-03-31 0.39 -43.56 8.60
2018-12-31 0.71 -36.49 8.36
2018-09-30 0.83 -29.67 6.86
2018-06-30 0.96 -15.41 6.93
2018-03-31 1.31 -11.10 6.09
2017-12-31 1.73 -7.78 4.58
2017-09-30 2.34 -4.51 3.95
2017-06-30 2.95 -6.82 2.31
2017-03-31 2.95 -3.32 1.52
2016-12-31 2.95 -1.23 1.15
2015-12-31 0.49 -0.37 0.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alpine Immune Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alpine Immune Sciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alpine Immune Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alpine Immune Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alpine Immune Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALPN Health

 How is Alpine Immune Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alpine Immune Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alpine Immune Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alpine Immune Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alpine Immune Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 11.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alpine Immune Sciences Company Filings, last reported 5 months ago.

NasdaqGM:ALPN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 34.83 4.89 46.59
2019-06-30 45.42 3.27 55.57
2019-03-31 56.58 3.74 63.96
2018-12-31 44.59 4.20 52.30
2018-09-30 54.98 4.67 61.98
2018-06-30 66.55 5.12 69.95
2018-03-31 73.88 5.08 76.65
2017-12-31 78.92 5.03 81.24
2017-09-30 82.97 4.99 87.20
2017-06-30 25.48 4.95 31.10
2017-03-31 12.16 0.00 13.57
2016-12-31 10.08 0.11 11.82
2015-12-31 0.26 0.00 5.42
  • Alpine Immune Sciences's level of debt (12.7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Alpine Immune Sciences's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alpine Immune Sciences has sufficient cash runway for 1.2 years based on current free cash flow.
  • Alpine Immune Sciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 61.3% each year.
X
Financial health checks
We assess Alpine Immune Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alpine Immune Sciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALPN Dividends

 What is Alpine Immune Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alpine Immune Sciences dividends.
If you bought $2,000 of Alpine Immune Sciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alpine Immune Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alpine Immune Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ALPN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ALPN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alpine Immune Sciences has not reported any payouts.
  • Unable to verify if Alpine Immune Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alpine Immune Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alpine Immune Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Alpine Immune Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alpine Immune Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alpine Immune Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALPN Management

 What is the CEO of Alpine Immune Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mitch Gold
COMPENSATION $1,045,690
AGE 51
TENURE AS CEO 3.8 years
CEO Bio

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the Executive Chairman, Chief Executive Officer and Assistant Secretary at Nivalis Therapeutics, Inc. since July 24, 2017. He was the Founder and Executive Chairman of Alpine Biosciences, Inc. Dr. Gold was the Founder and Managing Partner of Alpine BioVentures, GP, LLC. He served as the Chief Executive Officer and President of Dendreon Corp. from January 1, 2003 to February 1, 2012. He served as Vice President of Business Development at Dendreon from June 2001 to May 2002 and also served as its Chief Business Officer from May 2002 to December 2002. He served as an Executive Chairman of Dendreon Corp. from January 2012 to June 30, 2012 and served as its Executive Director from May 2002 to February 2013. From April 2000 to May 2001, he served as Vice President of Business Development and Vice President of Sales and Marketing for Data Critical Corporation. He was the Co-Founder of Elixis Corporation and also served as its Chief Executive Officer and President from 1995 to April 2000. Dr. Gold was a Resident Physician in the Department of Urology at the University of Washington. Dr. Gold serves as a Trustee of Cancer Research Institute, Inc. He has been a Director of SillaJen Biotherapeutics, Inc. since April 2012. Dr. Gold serves on the board of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute. For his contributions to science and the treatment of cancer he was named a runner-up for Smartest CEO by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. He was voted Entrepreneur of the Year in the Pacific Northwest in 2011 by Ernst and Young, as well as the top influencer in medicine in 2010 by Seattle Magazine. Dr. Gold was a Urology resident at the University of Washington. He has M.D. from Rush Medical College of Rush University Medical Center in 1993. Dr. Gold also earned a B.S. in Biology from the University of Wisconsin-Madison in 1989.

CEO Compensation
  • Mitch's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mitch's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Alpine Immune Sciences management team in years:

1.7
Average Tenure
51
Average Age
  • The average tenure for the Alpine Immune Sciences management team is less than 2 years, this suggests a new team.
Management Team

Mitch Gold

TITLE
Executive Chairman & CEO
COMPENSATION
$1M
AGE
51
TENURE
3.8 yrs

Stanford Peng

TITLE
President and Head of Research & Development
COMPENSATION
$2M
AGE
48
TENURE
0.9 yrs

Paul Rickey

TITLE
Senior VP
AGE
40
TENURE
2.9 yrs

Wayne Gombotz

TITLE
Chief Technology Officer
AGE
60
TENURE
0.8 yrs

Kristine Swiderek

TITLE
Senior Vice President of Research
TENURE
2.3 yrs

Jan Hillson

TITLE
Senior Vice President of Clinical Development
AGE
66
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Alpine Immune Sciences board of directors in years:

3.8
Average Tenure
57
Average Age
  • The tenure for the Alpine Immune Sciences board of directors is about average.
Board of Directors

Mitch Gold

TITLE
Executive Chairman & CEO
COMPENSATION
$1M
AGE
51
TENURE
5.2 yrs

Jamie Topper

TITLE
Independent Director
COMPENSATION
$105K
AGE
57
TENURE
3.8 yrs

Peter Thompson

TITLE
Independent Director
COMPENSATION
$104K
AGE
59
TENURE
3.8 yrs

Bob Conway

TITLE
Independent Director
COMPENSATION
$110K
AGE
65
TENURE
2.7 yrs

Andy Scharenberg

TITLE
Scientific Advisory Board Chairman

Jay Venkatesan

TITLE
Director
COMPENSATION
$198K
AGE
47
TENURE
3.8 yrs

Paul Sekhri

TITLE
Independent Director
COMPENSATION
$108K
AGE
61
TENURE
2.7 yrs

Manish Butte

TITLE
Member of Scientific Advisory Board

Paul Tumeh

TITLE
Member of Scientific Advisory Board

Chris Peetz

TITLE
Independent Director
COMPENSATION
$68K
AGE
40
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Jun 19 Buy James Rickey Individual 30. May 19 30. May 19 10,000 $4.95 $49,500
X
Management checks
We assess Alpine Immune Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alpine Immune Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALPN News

Simply Wall St News

Imagine Owning Alpine Immune Sciences (NASDAQ:ALPN) And Wondering If The 46% Share Price Slide Is Justified

That downside risk was realized by Alpine Immune Sciences, Inc. … View our latest analysis for Alpine Immune Sciences With just US$567,000 worth of revenue in twelve months, we don't think the market considers Alpine Immune Sciences to have proven its business plan. … A Different Perspective While Alpine Immune Sciences shareholders are down 46% for the year, the market itself is up 1.0%.

Simply Wall St -

Here's Why Alpine Immune Sciences (NASDAQ:ALPN) Might Be Better Off Without Debt

Check out our latest analysis for Alpine Immune Sciences What Is Alpine Immune Sciences's Debt? … NasdaqGM:ALPN Historical Debt, July 11th 2019 How Strong Is Alpine Immune Sciences's Balance Sheet? … If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

Simply Wall St -

What Kind Of Shareholder Owns Most Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Stock?

See our latest analysis for Alpine Immune Sciences NasdaqGM:ALPN Ownership Summary, June 12th 2019 What Does The Institutional Ownership Tell Us About Alpine Immune Sciences? … Alpine Immune Sciences already has institutions on the share registry. … Insider Ownership Of Alpine Immune Sciences The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Need To Know: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Insiders Have Been Buying Shares

The Last 12 Months Of Insider Transactions At Alpine Immune Sciences. … In the last twelve months, the biggest single purchase by an insider was when Patrick Heron bought US$2.0m worth of shares at a price of US$5.37 per share … Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$6.75

Simply Wall St -

Do Directors Own Alpine Immune Sciences Inc (NASDAQ:ALPN) Shares?

A look at the shareholders of Alpine Immune Sciences Inc (NASDAQ:ALPN) can tell us which group is most powerful. … Alpine Immune Sciences is a smaller company with a market capitalization of US$67m, so it may still be flying under the radar of many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Why Alpine Immune Sciences Inc's (NASDAQ:ALPN) Ownership Structure Is Important

In this article, I'm going to take a look at Alpine Immune Sciences Inc’s (NASDAQ:ALPN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … View our latest analysis for Alpine Immune Sciences

Simply Wall St -

Why I Sold Alpine Immune Sciences Inc (NASDAQ:ALPN)

There's room for improvement on the cash management side of things, but its overall debt level and interest coverage somwehat alleviates my doubts around the sustainability of the business going forward. … One reason I do like ALPN as a business is its low level of fixed assets on its balance sheet (1.28% of total assets). … A good company is reflected in its financials, and for ALPN, the financials don't look good.

Simply Wall St -

Who Are The Major Shareholders Of Alpine Immune Sciences Inc (ALPN)?

See our latest analysis for ALPN NasdaqGM:ALPN Ownership Summary Nov 25th 17 Institutional Ownership Institutions account for 10.26% of ALPN's outstanding shares, a significant enough holding to move stock prices if they start buying and selling in large quantities, especially when there are relatively small amounts of shares available on the market to trade. … ALPN insiders hold a not-so-significant 1.13% stake in the company, which somewhat aligns their interests with that of shareholders. … I suggest investors seek some degree of margin of safety due to high institutional ownership in ALPN, in particular due to the strong presence of active hedge fund investors.

Simply Wall St -

ALPN Company Info

Description

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Details
Name: Alpine Immune Sciences, Inc.
ALPN
Exchange: NasdaqGM
Founded:
$48,326,338
18,587,768
Website: http://www.alpineimmunesciences.com
Address: Alpine Immune Sciences, Inc.
201 Elliott Avenue West,
Suite 230,
Seattle,
Washington, 98119,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ALPN Common Stock Nasdaq Global Market US USD 25. Jul 2017
DB 34LA Common Stock Deutsche Boerse AG DE EUR 25. Jul 2017
Number of employees
Current staff
Staff numbers
48
Alpine Immune Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:41
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/01/07
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.